Trial
NCT06592768
A Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Safety and Efficacy of Briquilimab in Participants With Allergic Asthma
Phase ITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Jasper Therapeutics, Inc.
Collaborators
—
Condition
Allergic Asthma
Intervention
Briquilimab
Why stopped
Sponsor Decision - terminated due to changes in company priorities and not related to safety concerns.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2025-09-16